Compared with the control group, treatment with MYC/KRAS chimeric siRNAs significantly reduced tumor burden, with 6 mice showing complete tumor regression by day 10; however, resistance did develop in several tumors (Supplemental Figure 14, B and C). This evidence concerns the gene KRAS and neoplasm.